District Court Denies Motion to Dismiss After Defendants Fail to Show Plaintiffs’ Diagnostic Claims Lacked an Inventive Concept

Sep 9, 2016

Reading Time : 2 min

The plaintiffs, Athena Diagnostics, Inc., Isis Innovation Ltd. and Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V., developed and patented a method for diagnosing patients with the autoimmune disorder Myasthenia Gravis. The majority of patients with Myasthenia Gravis produce antibodies that attack their acetyl choline receptors, which causes the patients to experience waning muscle strength throughout the day. These patients are typically diagnosed by tests that detect the presence of autoantibodies to acetyl choline receptors. Approximately 20 percent of patients suffering from Myasthenia Gravis, however, do not produce acetyl choline receptor autoantibodies. The inventors of the patent asserted in this case discovered that Myasthenia Gravis patients who do not produce autoantibodies to acetyl choline receptors instead produce IgG antibodies that attack the N-terminal domains of muscle specific tyrosine kinase (“MuSK”), a receptor that is located on the surface of neuromuscular junctions. Relying on this discovery, the inventors developed an alternative method for diagnosing Myasthenia Gravis based on the detection of MuSK-specific autoantibodies. The claimed diagnostic methods are performed by attaching a radioactive isotope to the MuSK receptor protein or fragments thereof, introducing it into a sample of body fluid, and then detecting the presence of any antibody-antigen complexes formed between the radiolabeled receptor and antibodies present in the body fluid.

Defendants moved to dismiss plaintiffs’ complaint for infringement, alleging that the asserted patent claimed a law of nature, namely that certain Myasthenia Gravis patients produce autoantibodies to MuSK. Defendants further alleged that the asserted claims lack an inventive concept because they utilize standard techniques well-known in the art to perform the diagnostic method. Plaintiffs argued that the radiolabeled MuSK protein used in their methods is not a naturally occurring protein, and consequently, the claims are not directed to a law of nature. Plaintiffs also argued that utilizing a non-naturally occurring protein in a combination of known procedures transforms the claims and makes them patent eligible.

Under the first step of the Alice test, the district court rejected the plaintiffs’ assertion that their claims were patent eligible because they include the use of a radiolabeled compound that is not naturally occurring. Instead, the district court described the focus of the diagnostic methods to be the interaction of radiolabeled MuSK and patient body fluid, and held the interaction of these molecules to be naturally occurring. Turning to step two of the Alice test, the district court held that it could not determine whether the claims of the asserted patent contained an inventive concept that transformed them into patent eligible subject matter. Specifically, the district court stated that it could not determine at the motion to dismiss stage whether the combinations of steps claimed in the asserted patents were merely a series of techniques standard in the art or whether they were sufficiently inventive to deserve patent protection because it would be required to make factual determinations that went beyond what was apparent on the face of the complaint.

Athena Diagnostics, Inc. v. Mayo Collaborative Servs., LLC, C.A. No. 15-cv.40075-IT (D. Mass. Aug. 25, 2016).

Share This Insight

Previous Entries

IP Newsflash

November 5, 2024

The Federal Circuit vacated a district court’s fee award because the district court considered certain information that was not relevant to the question of whether plaintiff’s case was exceptional. Specifically, the Federal Circuit held that only those “red flags” that related to the successful Section 101 defense, which served as the basis for the district court’s grant of summary judgment, could be used to show the case was fatally flawed.   

...

Read More

IP Newsflash

November 1, 2024

The Federal Circuit’s decision in Kyocera Senco Industrial Tools Inc. v. International Trade Commission articulated a bright-line test for patent expert admissibility: to testify from the perspective of a “person of ordinary skill in the art” (POSITA), the expert must at least meet the definition of a POSITA for the patents-in-suit. Absent that level of skill, Kyocera holds that the witness’s testimony is not sufficiently reliable or relevant enough to be relied on by a fact-finder.

...

Read More

IP Newsflash

October 29, 2024

The PTAB denied a petitioner’s motion to compel routine discovery that sought information from a parallel ITC investigation for alleged inconsistent positions taken by patent owner in the IPR. The board found that patent owner had not taken inconsistent positions but warned patent owner that it had an ongoing duty to produce any information inconsistent with arguments made during the present IPR, even if that information related to arguments patent owner had dropped at the ITC.

...

Read More

IP Newsflash

October 11, 2024

The Central District of California ruled that the heightened pleading standard of Federal Rule of Civil Procedure 9(b) applies to all three prongs of a false patent marking claim, including the third prong, competitive injury. In doing so, took a clear stand on an issue with a nationwide split among district courts.

...

Read More

IP Newsflash

October 10, 2024

In a patent case containing a variety of federal and state law claims, the District of Massachusetts retained supplemental jurisdiction over the state law claims even after all the federal law claims were dismissed.

...

Read More

IP Newsflash

October 3, 2024

The Federal Circuit recently upheld the USPTO’s authority under the estoppel provision 37 C.F.R. § 42.73(d)(3)(i) to prohibit a patent owner from obtaining patent claims that are not patentably distinct from claims previously declared unpatentable in inter partes review (IPR) proceedings. However, the court clarified that the regulation applies only to new claims or amended claims, not previously issued claims.

...

Read More

IP Newsflash

September 27, 2024

In Kyocera Senco Industrial Tools Inc. v. International Trade Commission, the Federal Circuit held that an expert must meet the definition of a “person of ordinary skill in the art” of the asserted patents in order to opine on infringement, among other issues. This new bright-line test and the underlying rationale, however, raised several new questions regarding expert admissibility. SeeFederal Circuit: Narrow Definition of Skill in the Art Dooms Expert’s Testimony” and “Grappling With A Bright-Line Patent Expert Admissibility Test.” The Federal Circuit recently addressed one of those questions, namely whether an expert must have acquired the requisite level of skill as of the time of the invention or whether it is sufficient for an expert to acquire that knowledge at a later date.

...

Read More

IP Newsflash

September 23, 2024

The Director of the USPTO initiated sua sponte review of a PTAB panel’s decision to impose sanctions based on patentee’s conduct during IPR proceedings. The PTAB cancelled all of patentee’s claims, including those not unpatentable on the merits, after finding that patentee deliberately withheld data relevant to the patentability of the claims at issue. In her review, the Director addressed which regulations are implicated upon a party’s misconduct during AIA proceedings and addressed whether entry of judgment in the trial was an appropriate sanction.

...

Read More

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.